Table.

Base-Case Results of HCV Treatment

Combined Sofosbuvir and Ledipasvir Treatment Strategya	Base-Case Results
	Costs, $		QALYs		ICER, $ per QALY Gainedb
	Total Treatment	Incremental	Total	Incremental Gain
Treat all vs treat at stages F3 and F4
Treat at stage F3 or stage F4c	60 906	NA	14.09	NA	NA
Treat alld	89 804	28 899	14.82	0.73	39 475
By fibrosis stage
No treatment	46 107	NA	11.82	NA	NA
Treat at stage F4	57 616	11 509	12.85	1.02	11 252
Treat at stage F3	60 906	14 798	14.09	2.27	6522
Treat at stage F2	71 913	11 007	14.65	0.55	19 833
Treat at stage F1	83 594	11 682	14.79	0.14	81 165
Treat all	89 804	6210	14.82	0.03	187 065

Abbreviations: HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; NA, not applicable; QALY, quality-adjusted life-year.

^aSixty-seven percent of the patients with fibrosis stages F0 to F3 received 8 weeks of treatment and 33%received 12 weeks; all patients with stage F4 received 12 weeks.

^bGenerated by comparing each policy with the one above (next least expensive).

^cIndicates wait and treat only when patients reach stages F3 and F4.

^dIndicates treat all patients as soon as they are identified with HCV in any fibrosis stage.